Adherium Ltd Cash Flow Conversion Efficiency
Adherium Ltd cash flow conversion efficiency. Based on the latest financial reports, Adherium Ltd (ADR) has a cash flow conversion efficiency ratio of 9.437x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-7.43 Million ≈ $-5.26 Million USD) by net assets (AU$-787.24K ≈ $-557.02K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adherium Ltd (2013–2025)
Cash flow conversion efficiency of Adherium Ltd from 2013 to 2025. This chart illustrates how Adherium Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Adherium Ltd for real-time trading data and today's change.
Adherium Ltd Cash Flow Conversion Ratio Explained
Adherium Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adherium Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adherium Ltd ranked by their cash flow conversion efficiency. Also see ADR market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MRG Metals Ltd
AU:MRQ
|
-0.043x |
|
Merko Gida Sanayi ve Ticaret AS
IS:MERKO
|
-0.019x |
|
Thai Setakij Insurance PCL
BK:TSI
|
-0.190x |
|
Begbies Traynor Group PLC
LSE:BEG
|
-0.014x |
|
Precomp Solutions AB Series B
ST:PCOM-B
|
-0.069x |
|
Vast Renewables Limited Ordinary Shares
NASDAQ:VSTE
|
0.148x |
|
Planet Properindo Jaya Pt
JK:PLAN
|
-0.004x |
|
Innovotech Inc
V:IOT
|
-0.247x |
Annual Cash Flow Conversion Efficiency for Adherium Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Adherium Ltd from 2013 to 2025. Review ADR free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$-4.76 Million ≈ $-3.37 Million |
AU$-9.98 Million ≈ $-7.06 Million |
2.096x | +227.98% |
| 2024-06-30 | AU$6.48 Million ≈ $4.59 Million |
AU$-10.61 Million ≈ $-7.51 Million |
-1.638x | -62.64% |
| 2023-06-30 | AU$9.21 Million ≈ $6.52 Million |
AU$-9.28 Million ≈ $-6.56 Million |
-1.007x | +41.98% |
| 2022-06-30 | AU$5.54 Million ≈ $3.92 Million |
AU$-9.61 Million ≈ $-6.80 Million |
-1.736x | -116.08% |
| 2021-06-30 | AU$14.04 Million ≈ $9.93 Million |
AU$-11.27 Million ≈ $-7.98 Million |
-0.803x | +62.85% |
| 2020-06-30 | AU$3.38 Million ≈ $2.39 Million |
AU$-7.32 Million ≈ $-5.18 Million |
-2.162x | +84.80% |
| 2019-06-30 | AU$830.00K ≈ $587.28K |
AU$-11.81 Million ≈ $-8.35 Million |
-14.225x | -1754.91% |
| 2018-06-30 | AU$12.81 Million ≈ $9.06 Million |
AU$-9.82 Million ≈ $-6.95 Million |
-0.767x | -50.35% |
| 2017-06-30 | AU$22.70 Million ≈ $16.07 Million |
AU$-11.58 Million ≈ $-8.19 Million |
-0.510x | -76.99% |
| 2016-06-30 | AU$27.46 Million ≈ $19.43 Million |
AU$-7.91 Million ≈ $-5.60 Million |
-0.288x | -43364.50% |
| 2015-06-30 | AU$34.53 Million ≈ $24.43 Million |
AU$23.00K ≈ $16.27K |
0.001x | +100.07% |
| 2014-06-30 | AU$2.17 Million ≈ $1.53 Million |
AU$-2.16 Million ≈ $-1.53 Million |
-0.998x | +0.00% |
| 2014-03-31 | AU$2.31 Million ≈ $1.64 Million |
AU$-2.31 Million ≈ $-1.63 Million |
-0.998x | -24548.25% |
| 2013-06-30 | AU$3.50 Million ≈ $2.48 Million |
AU$-14.19K ≈ $-10.04K |
-0.004x | -- |
About Adherium Ltd
Adherium Limited, a digital health company, develops, manufactures, and supplies digital health technologies that address sub-optimal medication use in chronic diseases in New Zealand, Australia, Europe, and North America. The company offers Hailie Smartinhaler, a system for management of chronic respiratory conditions, including asthma and chronic obstructive pulmonary disease. It also provides … Read more